Dr. Escorcia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Avenue
New York, NY 10065Phone+1 212-639-2000
Summary
- I am a board-certified radiation oncologist and scientist committed to improving the quantity and quality lives of people with cancer.
Clinically, I treat patients with cancers amenable to radiotherapy, with particular interest in cancers of the gut, including liver and pancreas cancers.
For my research, I leverage my expertise in bioengineering, chemistry, pharmacology, and oncology to design, engineer, and test of novel tumor-selective imaging and therapeutic agents for human cancers in general, and liver cancers in particular, with translational intent.
I have brought together motivated trainees, and scientists to form the Laboratory of Molecular Radiotherapy within the Molecular Imaging Branch at the National Cancer Institute, with goals to
1) identify tumor selective targets,
2) discover novel biomolecules specific to targets of interest,
3) design, engineer, and test novel radioconjugates from these biomolecules using in vitro assays and in vivo imaging and therapy studies, and
4) conduct clinical studies using next generation radiopharmaceutical imaging and therapeutic agents.
Education & Training
- Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2013 - 2017
- Weill Cornell MedicineClass of 2012
Certifications & Licensure
- NY State Medical License 2013 - 2025
- American Board of Radiology Radiation Oncology
Publications & Presentations
PubMed
- Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups.Colleen P Olkowski, Falguni Basuli, Bruna Fernandes, Behnaz Ghaemi, Jianfeng Shi
Molecular Pharmaceutics. 2025-01-06 - Prognostic significance of tertiary lymphoid structures in gastric neuroendocrine carcinoma with association to delta-like ligand 3 and neuroendocrine expressions.Bokyung Ahn, Deokhoon Kim, Mi-Ju Kim, Seo-Rin Jeong, In Hye Song
Gastric Cancer. 2025-01-01 - Author Correction: CHIP ameliorates nonalcoholic fatty liver disease via promoting K63- and K27-linked STX17 ubiquitination to facilitate autophagosome-lysosome fusion.Hyunjin Rho, Seungyeon Kim, Seung Up Kim, Jeong Won Kim, Sang Hoon Lee
Nature Communications. 2024-12-04
External Links
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: